Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The cost-effectiveness of screening for chronic hepatitis B infection in the United States.

Eckman MH, Kaiser TE, Sherman KE.

Clin Infect Dis. 2011 Jun;52(11):1294-306. doi: 10.1093/cid/cir199. Epub 2011 May 2.

2.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

3.

Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.

John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M.

Pharmacoeconomics. 2012 Nov 1;30(11):1015-34. doi: 10.2165/11597660-000000000-00000. Review.

PMID:
23050771
4.

Entecavir for the treatment of chronic hepatitis B infection.

Shepherd J, Gospodarevskaya E, Frampton G, Cooper K.

Health Technol Assess. 2009 Oct;13 Suppl 3:31-6. doi: 10.3310/hta13suppl3/05. Review.

5.

Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.

Sun X, Qin WX, Li YP, Jiang XH.

J Gastroenterol Hepatol. 2007 Sep;22(9):1369-77. Review.

PMID:
17716343
6.

Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation.

Chou R, Dana T, Bougatsos C, Blazina I, Khangura J, Zakher B.

Ann Intern Med. 2014 Jul 1;161(1):31-45. doi: 10.7326/M13-2837. Review.

PMID:
24861032
7.

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.

Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A.

Health Technol Assess. 2009 Jul;13(35):1-172, iii. doi: 10.3310/hta13350. Review.

8.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
9.

A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.

Takeda A, Jones J, Shepherd J, Davidson P, Price A.

J Viral Hepat. 2007 Feb;14(2):75-88. Review.

PMID:
17244247
10.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

11.

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.

Jones J, Colquitt J, Shepherd J, Harris P, Cooper K.

Health Technol Assess. 2010 May;14 Suppl 1:23-9. doi: 10.3310/hta14Suppl1/04. Review.

12.

Pharmacoeconomics of entecavir treatment for chronic hepatitis B.

You JH, Chan FW.

Expert Opin Pharmacother. 2008 Oct;9(15):2673-81. doi: 10.1517/14656566.9.15.2673 . Review.

PMID:
18803453
13.

Treatment of chronic hepatitis B: Evolution over two decades.

Yuen MF, Lai CL.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:138-43. doi: 10.1111/j.1440-1746.2010.06545.x. Review.

PMID:
21199525
14.

Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer.

Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G.

Health Technol Assess. 2010 Nov;14(53):iii-iv, ix-x, 1-101. doi: 10.3310/hta14530. Review.

15.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL.

Clin Gastroenterol Hepatol. 2004 Feb;2(2):87-106. Review.

PMID:
15017613
16.

Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.

Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M.

Eur J Gastroenterol Hepatol. 2008 Apr;20(4):320-6. doi: 10.1097/MEG.0b013e3282f340c8. Review.

PMID:
18334876
17.

Selecting appropriate management strategies for chronic hepatitis B: who to treat.

McMahon BJ.

Am J Gastroenterol. 2006;101 Suppl 1:S7-12. Review.

PMID:
16448451
18.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

19.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

20.

Epidemiology of hepatitis B in the United States.

Kim WR.

Hepatology. 2009 May;49(5 Suppl):S28-34. doi: 10.1002/hep.22975.

Items per page

Supplemental Content

Write to the Help Desk